Advertisement

The Antiperinuclear Factor (APF) and Antikeratin Antibodies (AKA) in Rheumatoid Arthritis

  • R. M. Hoet
  • W. J. van Venrooij

Abstract

The diagnosis of rheumatoid arthritis (RA) is first of all based on clinical manifestations. Serological support for such a diagnosis is not very well established and it is based mainly on the presence of rheumatoid factors (RF). A positive RF test has a predictive value [1] and is related to disease with a more severe outcome [2]. However, RF is also present in other (autoimmune) diseases and in control sera from healthy persons [3]. Therefore, testing for a second RA-specific antibody would be very useful, and might even be necessary for the management of seronegative RA patients.

Keywords

Rheumatoid Arthritis Patient Stratum Corneum Keratohyalin Granule Rheumatoid Arthritis Seron Buccal Mucosa Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Valkenburg HA, Ball J, Burch TA et al. (1966) Rheumatoid factors in a rural population. Ann Rheum Dis 25:497–508PubMedGoogle Scholar
  2. 2.
    Kellgren JH, O’Brien WH (1962) On the natural history of rheumatoid arthritis in relation to sheep cell agglutination test (SCAT). Arthritis Rheum 5:115Google Scholar
  3. 3.
    Waller MV, Toone EC, Vaughan E (1964) Study of rheumatoid factor in a normal population. Arthritis Rheum 7:513PubMedCrossRefGoogle Scholar
  4. 4.
    Nienhuis RLF, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 23:302–305PubMedCrossRefGoogle Scholar
  5. 5.
    Smit JW, Sondag-Tschroots IRJM, Aaij C, Feltkamp TEW, Feltkamp-Vroom TM (1980) The antiperinuclear factor. II. A light-microscopical and immunofluorescence study on the antigenic substrate. Ann Rheum Dis 39:381–386PubMedCrossRefGoogle Scholar
  6. 6.
    Hoet RM, Arends M, Boerbooms AMTh, van Venrooij WJ (1991) The antiperinuclear factor, a marker autoantibody for rheumatoid arthritis. Co-localization of the perinuclear factor and profilaggrin. Ann Rheum Dis 50:611–619PubMedCrossRefGoogle Scholar
  7. 7.
    Visconti A, Cava L, Fontana G (1964) Ricerca del fattore antiperinucleare (APF) nell’artrite reumatoide ed in altre malattie. Osp Magg 59:1357Google Scholar
  8. 8.
    Marmont AM, Damasio EE, Bertorello C, Rossi F (1967) Studies on the antiperinuclear factor. Arthritis Rheum 10:117–128PubMedCrossRefGoogle Scholar
  9. 9.
    Roques MT (1969) Les anticorps dits périnucléaires. Thesis, ParisGoogle Scholar
  10. 10.
    Sondag-Tschroots IRJM, Aaij C, Smit JW, Feltkamp TEW (1979) The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis 38:248–251PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson GD, Carvalho A, Holborow EJ, Goddard DH, Russel G (1981) Antiperinuclear factor and antikeratin antibodies in rheumatoid arthritis. Ann Rheum Dis 40:263–266PubMedCrossRefGoogle Scholar
  12. 12.
    Cassani F, Ferri S, Bianchi FB, Zauli D, Pisi E (1983) Antiperinuclear factor in an Italian series of patients with rheumatoid arthritis. Ric Clin Lab 13:347–352PubMedGoogle Scholar
  13. 13.
    Youinou P, Le Goff P, Miossec P (1983) Untersuchungen zur Beziehung zwischen antiperinucleären Faktoren, Anti-keratin-antikörpern und dem agglutinierenden und nicht agglutinierenden Rheumafactor bei der chronischen Polyarthritis. Z. Rheumatol 42:36–39PubMedGoogle Scholar
  14. 14.
    Kataaha PK, Mortazavi-Milani SM, Russel G, Holborow EJ (1985) Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis. Ann Rheum Dis 44:446–449PubMedCrossRefGoogle Scholar
  15. 15.
    Westgeest AA, Boerbooms AMTh, Jongmans M, Vandenbroucke JP, Vierwinden G, van de Putte LBA (1987) Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 14:893–897PubMedGoogle Scholar
  16. 16.
    Janssens X, Veys EM, Verbruggen G, Declercq L (1988) The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 15:1346–1350PubMedGoogle Scholar
  17. 17.
    Vivino FB, Maul GG (1990) Histologic and electron microscopic characterization of the antiperinuclear factor antigen. Arthritis Rheum 33:960–969PubMedCrossRefGoogle Scholar
  18. 18.
    Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ (1979) Antikeratin antibodies in rheumatoid arthritis. Br Med J 2:97–99PubMedCrossRefGoogle Scholar
  19. 19.
    Scott DL, Delamere JP, Jones LJ, Walton KW (1981) Significance of laminar antikeratin antibodies to rat oesophagus in rheumatoid arthritis. Ann Rheum Dis 40:267–271PubMedCrossRefGoogle Scholar
  20. 20.
    Ordeig J, Guardia J (1984) Diagnostic value of antikeratin antibodies in rheumatoid arthritis. J Rheumatol 11:602–604PubMedGoogle Scholar
  21. 21.
    Hajiroussou VJ, Skingle J, Gillett AP, Webley M (1985) Significance of antikeratin antibodies in rheumatoid arthritis. J Rheumatol 12:57–59PubMedGoogle Scholar
  22. 22.
    Mallya RK, Young BJJ, Pepys MB, Hamblin TJ, Mace BEW, Hamilton EBD (1983) Antikeratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol 51:17–20PubMedGoogle Scholar
  23. 23.
    Kirnstein H, Mathiesen FK (1987) Antikeratin antibodies in rheumatoid arthritis. Scand J Rheumatology 16:331–337CrossRefGoogle Scholar
  24. 24.
    Youinou P, Le Goff P, Colaco CB, Thivolet J, Tater D, Viac J, Shipley M (1985) Antikeratin antibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases. Ann Rheum Dis 44:450–454PubMedCrossRefGoogle Scholar
  25. 25.
    Meyer O, Fabregas D, Cyna L, Ryckewaert A (1986) Les anticorps antikératine. Un marqueur des polyarthrites rhumatoïdes évolutives. Rev Rhum Mal Osteoartic 53:601–605PubMedGoogle Scholar
  26. 26.
    Vincent C, Serre G, Lapeyre F, Fournié B, Ayrolles C, Fournié A, Soleilhavoup J-P (1989) High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called antikeratin antibodies. Ann Rheum Dis 48:712–722PubMedCrossRefGoogle Scholar
  27. 27.
    Quismorio PF, Kaufman RL, Beardmore T, Mongan ES (1983) Reactivity of serum antibodies to the keratin layer of rat esophagus in patients with rheumatoid arthritis. Arthritis Rheum 4:494–499CrossRefGoogle Scholar
  28. 28.
    Kurki P, Helve T, Virtanen I (1983) Antibodies to cytoplasmic intermediate filaments in rheumatic diseases. J Rheumatol 10:558–562PubMedGoogle Scholar
  29. 29.
    Senecal JL, Rothfield NF, Oliver JM (1982) Immunoglobulin M autoantibody to vimentin intermediate filaments. J Clin Invest 69:716–721PubMedCrossRefGoogle Scholar
  30. 30.
    Kurki P, Virtanen I (1984) The detection of human antibodies against cytoskeletal components. J Immunol Methods 67:209–223PubMedCrossRefGoogle Scholar
  31. 31.
    Osung OA, Chandra M, Holborow EJ (1982) Intermediate filaments in synovial lining cells in rheumatoid arthritis and other arthritides are of the vimentin type. Ann Rheum Dis 41:74–77PubMedCrossRefGoogle Scholar
  32. 32.
    Toh BH, Sotelo YJ, Osung O, Holborow EJ, Kanakoudi F, Small JV (1979) Viral infections and IgM autoantibodies to cytoplasmic intermediate filaments. Clin Exp Immunol 37:76–82PubMedGoogle Scholar
  33. 33.
    Alcover A, Molano J, Renart J, Gil-Aguado A, Nieto A, Avila J (1984) Antibodies to vimentin intermediate filaments in sera from patients with systemic lupus erythematosus. Arthritis Rheum 8:922–928CrossRefGoogle Scholar
  34. 34.
    Osung OA, Chandra M, Holborow EJ (1982) Antibody to intermediate filaments of the cytoskeleton in rheumatoid arthritis. Ann Rheum Dis 41:69–73PubMedCrossRefGoogle Scholar
  35. 35.
    Senecal JL, Olivier JM, Rothfield N (1985) Anticytoskeletal autoantibodies in the connective tissue diseases. Arthritis Rheum 28:889–895PubMedCrossRefGoogle Scholar
  36. 36.
    Westgeest AAA (1988) Autoantibodies in rheumatic diseases, Chap 7. Rheumatoid arthritis and autoantibodies: a review of the literature on antinuclear antibody and antiperinuclear factor. Thesis, University of NijmegenGoogle Scholar
  37. 37.
    Westgeest AAA, Boerbooms AMTh, van de Putte LBA (1990) The influence of serum dilution on findings of antiperinuclear factor prevalence in rheumatoid arthritis. Arthritis Rheum 33:759–760PubMedCrossRefGoogle Scholar
  38. 38.
    Youinou P, Le Goff P, Dumay A, Lelong A, Fauquert P, Jouquan J (1990) The antiperinuclear factor. I. Clinical and serologic associations. Clin Exp Rheum 8:1–6Google Scholar
  39. 39.
    Youinou P, Pennec P, Le Goff P (1984) Antiperinuclear factor in Sjögren’s syndrome in the presence or absence of rheumatoid arthritis. Clin Exp Rheumatol 2:5–9PubMedGoogle Scholar
  40. 40.
    Youinou P, Massé R, Peu-Duvallon P, Le Roux P, Grulier A, Miossec P, Dorval J-C, Lizan G, Férec C, Le Goff P (1982) Anticorps antipérinucléaires dans le psoriasis. Ann Dermatol Venereol 109:359–364PubMedGoogle Scholar
  41. 41.
    Youinou P, Le Goff P, Casburn-Budd R, Ferec C, Pennec Y (1984) Evidence for relationships between antiperinuclear and IgG rheumatoid factor. Rheumatol Int 4:111–114PubMedCrossRefGoogle Scholar
  42. 42.
    Scherbaum WA, Youinou P, Le Goff P, Bottazzo GF (1984) Anti-perinuclear and rheumatoid factor in different forms of autoimmune thyroid disease. Clin Exp Immunol 55:516–518PubMedGoogle Scholar
  43. 43.
    Youinou P, Le Goff P, Miossec P, L’Hostis D, Pennec Y, Schwarzberg C, Ferrec C (1983) Intérêt des anticorps anti-périnucléaires dans le diagnostic et le pronostic de la polyarthrite rhumatoïde. Rev Rhum Mal Osteoartic 50:441–446PubMedGoogle Scholar
  44. 44.
    Westgeest AAA, van Loon AM, van der Logt JTM, van de Putte LBA, Boerbooms AMTh (1989) Antiperinuclear factor, a rheumatoid arthritis specific autoantibody: its relation to Epstein-Barr virus. J Rheumatol 16:626–630PubMedGoogle Scholar
  45. 45.
    Youinou P, Zabba C, Eveillaud C, Dewitte JD, Kerbourc’h JF, Ferec C, Clavier J (1984) Antiperinuclear activity in lung carcinoma patients. Cancer Immunol Immunother 2:80–81Google Scholar
  46. 46.
    Youinou P, Miossec P, Pennec Y, Boles JM, Le Goff P, Le Menn G (1983) Anticorps anti-périnucléaires et anti-kératine au cours des maladies du foie. Sem Hop Paris 59:589–592PubMedGoogle Scholar
  47. 47.
    Boerbooms AMTh, Westgeest AAA, Reekers P, van de Putte LBA (1990) Immunogenetic heterogeneity of seronegative rheumatoid arthritis and the perinuclear factor. Ann Rheum Dis 49:15–17PubMedCrossRefGoogle Scholar
  48. 48.
    Holbrook KA (1989) Biologic structure and function: perspectives on morphologic approaches to the study of the granular layer keratinocyte. J Invest Dermatol 4S: 84S–104SCrossRefGoogle Scholar
  49. 49.
    Dale BA, Holbrook KA, Kimball JR, Hoff M, Sun T-T (1985) Expression of epidermal keratins and filaggrin during fetal skin development. J Cell Biol 101:1257–1269PubMedCrossRefGoogle Scholar
  50. 50.
    Hoet RM, Voorsmit R, van Venrooij WJ (1991) Keratohyalin granules of cultured buccal mucosa cells do not contain the perinuclear factor. Clin Exp Immul 84:59–65CrossRefGoogle Scholar
  51. 51.
    Allday MJ, Crawford DH (1988) Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. Lancet 1:855–857PubMedCrossRefGoogle Scholar
  52. 52.
    Youinou P, Seigneurin JM, Le Goff P, Dumay A, Vicariot M Lelong A (1990) The antiperinuclear factor. II. Variability of the perinuclear antigen. Clin Exp Rheumatol 8:1–5Google Scholar
  53. 53.
    Miossec P, Youinou P, Le Goff P, Moineau MP (1982) Clinical relevance of antikeratin antibodies in rheumatoid arthritis. Clin Rheumatol 1:185–189PubMedCrossRefGoogle Scholar
  54. 54.
    Cooper C, Cotton DWK, Jones SK, Cawley MID, Young BJJ (1986) Antikeratin antibody in rheumatoid and psoriatic arthritis. Ann Rheum Dis 145:349–350CrossRefGoogle Scholar
  55. 55.
    Serre G, Vincent C, Viraben R, Soleilhavoup J-P (1985) Autoantibodies to keratins in normal huma sera, systemic lupus erythematosus, rheumatoid arthritis and psoriasis. Eur J Clin Invest 115:A36Google Scholar
  56. 56.
    Feltkamp TEW, Boerbooms AMTh, De Keyser F, Dumais M, Hoet RM, van Venrooij WJ, Verbruggen G, Veys EM, Youinou P (1990) Antiperinuclear factor — standardization program. Clin Rheumatol 9:112–113CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. M. Hoet
    • 1
  • W. J. van Venrooij
    • 1
  1. 1.Department of BiochemistryUniversity of NijmegenNijmegenThe Netherlands

Personalised recommendations